EMORY UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160137731 | HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR - The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein. | 05-19-2016 |
20160113925 | METHODS OF TREATING CANCER WITH A COMBINATION OF GLUCOSE MODULATORS AND BCL-2 INHIBITORS - This disclosure relates to treating or preventing cancers, such as hematological malignancies, by administering a compound that binds BCL2 and one or more compounds that inhibit glucose or glutamine metabolism. In certain embodiments, the compounds that inhibit glucose metabolism are ritonavir optionally in combination with 6-diazo-5-oxo-L-norleucine or any derivative, prodrugs, or salts of these compounds. Contemplated BCL2 binding compounds are ABT-199 (venetoclax), ABT-263 (navitoclax), or ABT-737. | 04-28-2016 |
20160106684 | CASEIN COATED DRUG-LOADED IRON OXIDE NANOPARTICLES - This disclosure relates to nanoparticle drug delivery systems composed of casein (CN) coated nanoparticles, e.g., iron oxide nanoparticles coated with an inner layer and an out layer comprising the milk protein casein. In certain embodiments, drug molecules are incorporated into an inner polymeric layer coating the nanoparticles, which are subsequently coated with a casein containing outer layer, i.e., a layer-by-layer (LBL) construction. Oral administration of these casein coated nanoparticles are contemplated as experiments indicated sufficiently stability in conditions that simulate the conditions of the gut. Drugs that were loaded into the nanoparticle systems were released when the casein outer layer was gradually degraded in the presence of an intestinal protease meant to simulate conditions of the intestine. | 04-21-2016 |
20160095859 | COMBINATION THERAPIES FOR OVERCOMING RESISTANCE TO MITOTIC AGENTS DURING CHEMOTHERAPY - This disclosure relates to the uses of compounds that target an interaction between CHFR and PARP1. In certain embodiments, the disclosure relate to treating cancer by administering a mitotic inhibitor such as a taxane and a vinca alkaloid in combination with a compound that inhibits CHFR and PARP1 interactions, such as 5-((1-benzyl-1H-indol-3-yl)methylene)-1-(3,4-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione, derivatives or salts thereof, optionally in further combination with a third anti-cancer agent. | 04-07-2016 |
20160046930 | METHODS OF SEQUENCING NUCLEIC ACIDS IN MIXTURES AND COMPOSITIONS RELATED THERETO - This disclosure relates to analyzing the end-to-end sequence and the relative distributions in heterogeneous mixtures of polynucleotides and methods and enabling reagents related thereto. In certain embodiments this method relates to the complete full length sequencing and quantitative profiling of mRNAs present in the transcriptomes of cells or tissues of but not limited to, higher multicellular organisms that possess interrupted genes subject to complex post-transcriptional RNA processing | 02-18-2016 |
20160025717 | HYPOSIALYLATION DISORDERS - Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject, and determining the ratio of T to ST. | 01-28-2016 |
20150366933 | TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE - The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on | 12-24-2015 |
20150352190 | Modified Factor VIII - Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes. | 12-10-2015 |
20150239972 | METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS - PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist. | 08-27-2015 |
20150238593 | MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG AND POL GENES - The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes. | 08-27-2015 |
20150231227 | COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE - Novel plasmid constructs useful for the delivery of DNA vaccines are provided having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The constructs are useful for inducing in a patient an immune response against pathogenic viruses such as HIV, measles or influenza. Immunodeficiency virus vaccine inserts of the present invention express non-infectious HIV virus-like particles (VLP) bearing multiple viral epitopes. VLPs allow presentation of the epitopes to multiple histocompatability types. Also described are methods for immunizing a patient by delivery of a novel plasmid of the present invention to a patient. Optionally, the immunization protocol may include a booster vaccination that may be a live vector vaccine such as a recombinant pox virus or modified vaccinia Arbora vector having a transcription cassette expressing the same vaccine insert as the primary immunizing vector. | 08-20-2015 |
20150206302 | SYSTEMS, METHODS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR INTEGRATING FLUOROSCOPY VENOGRAM AND MYOCARDIAL IMAGES - Systems, methods, and computer-readable storage media relate to generate an integrated image including fluoroscopy venogram and myocardial image with left-ventricular (LV) contraction sequence and scar distribution. The method may include processing myocardial image to determine LV systolic and diastolic dyssynchrony, the processing including generating one or more quantitative indices, the quantitative indices including myocardial scar distribution and contraction sequence; generating an integrated image including myocardial image and fluoroscopy venogram data, the integrated image including at least one rank of lead placement quality. The fluoroscopy venogram data may be either 2D fluoroscopy venogram or 3D LV venous anatomy reconstructed from the 2D fluoroscopy venogram. | 07-23-2015 |
20150196540 | NMDA RECEPTOR MODULATORS AND USES RELATED THERETO - This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiments, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof. In certain embodiments, the disclosure relates to methods of treating or preventing nervous system disorders comprising administering an effective amount of a composition comprising compound disclosed herein to a subject in need thereof. | 07-16-2015 |
20150174273 | IMAGING AND THERAPEUTIC METHODS FOR TREATING PARATHYROID TUMORS - It has been discovered that human parathyroid tumor cells express high densities of folate receptors which could provide a target that may be used for localization. In certain embodiments, the disclosure relates to methods of detecting and imaging parathyroid tumors or canccrous cells in tissues using a folatc conjugate to enhance imaging techniques such as magnetic resonance imaging, positron emission tomography, computed tomography (CT), and single-photon emission computed tomography (SPECT). An image of radioactivities or nuclear magnetic resonance frequencies as a function of location for parcels (voxels), may be constructed and plotted. The image shows the tissues in which the tracer has become concentrated. | 06-25-2015 |
20150110723 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO - The disclosure relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidases (Nox enzymes) and/or myeloperoxidase. | 04-23-2015 |
20150072420 | THERAPEUTIC USE OF CD31 EXPRESSING CELLS - As described below, the present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells. | 03-12-2015 |
20150071987 | IMMUNOSTIMULATORY COMPOSITIONS, PARTICLES, AND USES RELATED THERETO - In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules. | 03-12-2015 |
20150064286 | PREPARATION AND COMPOSITIONS OF HIGHLY BIOAVAILABLE ZEROVALENT SULFUR AND USES THEREOF - The present invention features sulfur-rich compositions and preparations thereof that are safe and effective as hydrogen sulfide prodrugs of high bioavailability. The invention also includes methods of treating pathological conditions associated with oxidative stress using sulfur-rich compositions. The invention further includes sulfur-rich compositions as antidotes and medical food for preserving and promoting general health. | 03-05-2015 |
20150018275 | METHODS OF IMPROVING BEHAVIORAL THERAPIES - This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy. | 01-15-2015 |
20140378736 | METHODS, SYSTEMS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR GENERATING A RADIATION THERAPY TREATMENT PLAN - Methods, systems and computer-readable storage media relate to generating a treatment plan for a patient having a patient record. The methods, systems, and the computer-readable storage medias according to embodiments can automatically generate a treatment plan for the patient using (reference) records from previous plans. The system may include: a comparison module configured to compare anatomical information of a plurality of reference records and the patient record; a comparison quantification module configured to determine a metric corresponding to a degree of matching between each reference record and patient record; a reference record selection module configured to select a reference record from the plurality of reference records based on the metric; and a treatment plan generation module configured to generate a treatment plan for the patient based on the selected reference record. | 12-25-2014 |
20140364712 | NANOENHANCED HEMOSTATIC DEVICE AND METHODS FOR MAKING A LAYER HAVING HEMOSTATIC PROPERTIES - Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide. | 12-11-2014 |
20140350129 | DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK - This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individual's risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individual's risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), and/or anti-CMV antibody. | 11-27-2014 |
20140349984 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject. | 11-27-2014 |
20140348851 | ANTIBODIES DIRECTED AGAINST INFLUENZA - Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | 11-27-2014 |
20140348781 | CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS RELATED THERETO - In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-9 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-9 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids. | 11-27-2014 |
20140336143 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 11-13-2014 |
20140336071 | DEVICES, COMPOSITIONS, AND METHODS FOR MEASURING MOLECULES AND FORCES - This disclosure relates to compositions, devices and methods of detecting the presence of molecules and optionally quantifying forces associated with molecular interactions on the surface of cells and other lipids. In certain embodiments, devices disclosed herein can be used to detect forces through cell surface receptors. In other embodiments, the devices can be used to detect the presence or absence of molecules on cells or other particles or detect the changes in cell morphology after ligand receptor binding. | 11-13-2014 |
20140335079 | SOLENOPSIN AND DERIVATIVES, THERAPEUTIC COMPOSITIONS, AND METHODS RELATED THERETO - This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula: | 11-13-2014 |
20140329817 | MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED THERETO - This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I, or salt, prodrug, or ester thereof wherein X, Y, and R | 11-06-2014 |
20140329716 | DEVICES HAVING A CALIBRATION CONTROL REGION, SYSTEMS AND METHODS FOR IMMUNOHISTOCHEMICAL ANALYSES - The disclosure relates to devices, systems and methods that address the variability in immunohistochemistry (IHC) tests that can lead to inaccurate diagnosis or misdiagnosis while maintaining important structural information within the specimen. The devices may include a control region having a control unit including a plurality of substantially homogenous samples and a biological sample region. | 11-06-2014 |
20140328793 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS - Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient. | 11-06-2014 |
20140309280 | ASSAYS FOR MICRO-RNA-182 AS A BIOMARKER FOR MUSCLE ATROPHY AND THERAPEUTIC APPLICATIONS - In certain embodiments, this disclosure relates to assays for miR-182 and therapeutic applications. In certain embodiments, the disclosure relates to methods of evaluating a state of skeletal muscle atrophy comprising the steps of measuring miR-182 in a sample from a subject wherein decreased quantities of miR-182 indicates an increased state of muscle atrophy in the subject. | 10-16-2014 |
20140294818 | PGAM1 INHIBITORS AND METHODS RELATED THERETO - In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof. | 10-02-2014 |
20140294764 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO - This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes. | 10-02-2014 |
20140288013 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF CANCER USING 2-DG AND AN IGF-IR INHIBITOR - The disclosure relates to methods and compositions for the management of cancer. In certain embodiments, the disclosure relates to methods of treating or preventing cancer by administering an IGF-IR inhibitor and 2-deoxyglucose to a subject in need thereof. | 09-25-2014 |
20140271615 | HYPOSIALYLATION DISORDERS - Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder. In additional embodiments, these methods can be used to determine the lowest effective dosage of the therapeutic agent of use to treat the subject. | 09-18-2014 |
20140270447 | SYSTEMS, METHODS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR AUTOMATICALLY SEGMENTING IMAGES OF A REGION OF INTEREST - Systems, methods, and computer-readable storage media relate to segmenting an image series of at least one image of a region of interest of a subject. The methods, systems, and computer readable storage media can automatically segment interior and exterior boundaries relative to the region of interest (e.g., epicardial and endocardial boundaries with respect to a right ventricle) from an image series by combining sparse matrix transform, a training model, and a localized region based level set function. | 09-18-2014 |
20140261099 | SURGICAL SUPPORT DEVICE - A surgical support device can provide members for attaching various medical accessories in a safe, stable and secure manner. The surgical support device can also configured to isolate the sterile field from the non-sterile field to better enhance infectious control measures. The surgical support device may include at least two side supports configured to extend vertically from the side rail, each side support including a support member; a transverse member disposed between the two side supports; at least two support members; at least one platform configured to be pivotable between the transverse member and the support member; and at least one accessory arm extending from at least one of the at least two side supports and configured to pivot around the at least one of the at least two side supports; and a plurality of accessory attachment members configured to secure and/or support one or more accessories. | 09-18-2014 |
20140257215 | EXTENDED WEAR DEVICES FOR LIQUID DEODORIZERS AND CONTAINERS INCLUDING SUCH DEVICES - A device and container, including the device, are configured for deodorizing an effluent, e.g., bodily waste. The device can include a carrier configured to retain a deodorizer fluid and disperse the deodorizer fluid into the effluent; and a mesh film configured to at least partially envelope the carrier. The carrier can include an absorbent material configured to at least one of absorb, retain, and disperse the deodorizer fluid. The device may be removably or fixedly disposed with respect to a container configured to collect the effluent. The device may be preloaded with the deodorizer fluid. | 09-11-2014 |
20140255927 | RNA SPLICING ALTERATIONS AND U1 SMALL NUCLEAR RIBONUCLEOPROTEINS IN NEURODEGENERATIVE DISEASES - This disclosure relates to methods of diagnosing neurodegenerative disease by analyzing proteins or protein expression profiles in a subject, or RNA or RNA expression profiles in a subject. In certain embodiments, the disclosure contemplates the diagnosis of preclinical or symptomatic stages of Alzheimer's disease, mild cognitive impairment, or chronic traumatic encephalopathy by identification of components of U1 small nuclear ribonucleoproteins or fragments thereof which are capable of forming cytoplasmic tangle-like structures. | 09-11-2014 |
20140255517 | MANAGING POST-TRAUMATIC STRESS DISORDER - In certain embodiments, the disclosure relates to methods of treating or preventing posttraumatic stress disorder comprising administering a pharmaceutical composition comprising effective amount of an angiotensin-converting enzyme inhibitor to a subject in need thereof. In certain embodiments, the angiotensin-converting enzyme inhibitor is administered in combination with an angiotensin receptor blocker. | 09-11-2014 |
20140255441 | VLPS CONTAINING LIGANDS AND METHODS RELATED THERETO - This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen. | 09-11-2014 |
20140255426 | WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS - In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a Wnt pathway inhibitor optionally in combination with one or more anti-viral agents. In certain embodiments, the subject is diagnosed with a chronic viral infection such as human immunodeficiency virus (HIV). | 09-11-2014 |
20140249199 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO - The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula (I), pharmaceutical compositions having a compound of formula (I), and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula (I) to a subject in need thereof. | 09-04-2014 |
20140248372 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO - The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. | 09-04-2014 |
20140243968 | SYSTEMS, DEVICES AND METHODS FOR REPAIR OF HEART VALVE LESIONS - The systems and devices and methods relate to surgical and percutaneous repair of heart valve regions. The systems and devices are structured to conform to the desired shape of a specific patient. The devices may include a mounting structure and a valve support onto which leaflets of the valve may coapt or rest. The devices may be structured to be mounted directly onto a leaflet of the valve. | 08-28-2014 |
20140242068 | JAML SPECIFIC BINDING AGENTS, ANTIBODIES, AND USES RELATED THERETO - Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto. | 08-28-2014 |
20140235566 | PYRIMIDINE NUCLEOSIDES AND THEIR MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS AND CANCER - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, or HBV in human patients or other animal hosts. The compounds are certain N | 08-21-2014 |
20140221480 | METHODS OF MANAGING BRAIN INFLAMMATION - This disclosure relates to methods of managing brain injury such as inflammation due to trauma induced brain injury and ischemic stroke by administering resatorvid or derivative there of a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating cerebral ischemia comprising administering an effective amount of resatorvid to a subject in need thereof. In certain embodiments, the effective amount is 3 mg/kg. In certain embodiments, resatorvid is administered by injection. | 08-07-2014 |
20140220024 | CHYMASE COMPOSITIONS, ANTIBODIES, DIAGNOSTICS, AND THERAPEUTIC METHODS RELATED THERETO - The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of AVF nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments, the disclosure relates to methods of determining the effectiveness of creating an arteriovenous fistula in a subject diagnosed with chronic kidney disease. | 08-07-2014 |
20140219917 | OLIGOSACCHARIDE CONJUGATES FOR TARGETING BACTERIA AND USES RELATED THERETO - This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic. | 08-07-2014 |
20140213924 | METHODS, SYSTEMS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR DETERMINING RESPIRATORY INDUCED ORGAN MOTION - Methods, systems and computer-readable storage media relate to determining respiratory motion from motion data of a target to be treated. The methods may include processing motion data of a target to be treated obtained from at least one marker for at least one period. Each period including a plurality of time intervals. The processing including processing the motion data to determine an isocenter for each time interval along at least one of a plurality of axes of motion. The method may include determining at least one component of the motion data in at least one axis, the at least component corresponding to a subset of the motion data having a discrete value and/or a range of values; and determining respiratory motion from at least one component of the motion data. Radiotherapy treatment can be improved by determining the respiratory motion and the impact of respiration of a target. | 07-31-2014 |
20140212382 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2′-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations. | 07-31-2014 |
20140194422 | PIPERAZINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO - The disclosure relates to piperazine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidase. | 07-10-2014 |
20140193477 | COLLAGEN BASED MATERIALS AND USES RELATED THERETO - This disclosure relates to materials fabricated from collagen and uses relates thereto. Typically, layers of collagen are stretched during a curing period and optionally coated or impregnated with an elastin like protein. In certain embodiments, these materials can be used in tissue repair or arranged into cylinders and utilized as a prosthetic vascular graft. | 07-10-2014 |
20140187537 | METHODS OF PREDICTING OUTCOMES OF CHEMOTHERAPY TREATMENTS AND ALTERNATIVE THERAPIES - This disclosure relates to diagnostic and therapeutic methods and systems related thereto. In certain embodiments, the disclosure contemplates methods of improving chemotherapy treatments by administering chemotherapy agents, analyzing CHFR gene expression, methylation, or both, and determining an appropriate therapeutic strategy. Analysis of data herein revealed that reduced CHFR expression levels was a predictor of improved overall survival of subject with non-small cell lung cancer. | 07-03-2014 |
20140186949 | ENHANCING A POPULATION OF INSULIN RELEASING CELLS USING GFR Alpha-1 Agonists - Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-α1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation. | 07-03-2014 |
20140179919 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT - The present disclosure relates to organic chemistry and in particular to a series of corticotropin releasing factor type-1 (CRF | 06-26-2014 |
20140179750 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO - The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof. | 06-26-2014 |
20140178374 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO - The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof. | 06-26-2014 |
20140178370 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERSISTENT INFECTIONS AND CANCER BY INHIBITING THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY - The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer. | 06-26-2014 |
20140163302 | METHODS, SYSTEMS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR IMAGE-GUIDED TREATMENT PLANNING AND ASSESSMENT - Methods, systems and computer-readable storage media relate to image-guided treatment planning and treatment assessment. The methods, systems, and the computer-readable storage medias according to embodiments can analyze treatment response and can determine an accurate, outcome-based response assessment of treatment (e.g., radiation treatment). The methods may include a method for determining a treatment response. The method may include registering at least a first image data and a second image data of a subject, the first image data corresponding to a first time point, the second image data corresponding to a second time point, the first time point and the second time point being different with respect to a treatment session and/or treatment stage. The method may include processing the registered image to determine a treatment response. The registering may be based on deformable registration. | 06-12-2014 |
20140163093 | METHODS FOR TREATING INFLAMATORY CONDITIONS AND STATES, AND CANCERS BY ANTAGONIZING NF-kB ACTIVATION - The disclosure is directed to methods for treating inflammatory conditions and cancers that have misregulated NF-κB. In some embodiments, the disclosure is directed to methods for treating inflammatory conditions, inflammatory states associated with treating HIV and AIDS infections, and cancers that include administering strontium ranelate to a subject diagnosed with or at risk of inflammatory conditions, inflammatory states, and cancers, respectively. | 06-12-2014 |
20140155643 | DIRHODIUM CATALYST COMPOSITIONS AND SYNTHETIC PROCESSES RELATED THERETO - This disclosure relates to compositions comprising dirhodium catalysts and uses related thereto, e.g., in enantioselective transformations of donor/acceptor carbenoids. In certain embodiments, the dirhodium catalyst comprises a cyclopropyl ring substituted with a carboxylic acid ligand. In certain embodiments, the disclosure relates to compositions comprising a compound of the following formula, or salts thereof wherein, R | 06-05-2014 |
20140147411 | METHODS OF TREATING CANCER AND TESTING MUTATION ZYGOSITY RELATED THERETO - In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount a tyrosine kinase inhibitor in combination with an immunotherapy to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating cancer comprising: i) analyzing both chromosomes in a cell from a subject for the a V600E mutation of BRAF; and ii) determining if both of the chromosomes contain the V600E mutation, then treating the subject comprising the step of administering an effective amount a tyrosine kinase inhibitor in combination with an immunotherapy to the subject. | 05-29-2014 |
20140135288 | SELECTING USE OF PROTEASOME INHIBITORS BASED ON NF-KB2 SEQUENCE - Provided herein are methods for selecting use of proteasome inhibitors. | 05-15-2014 |
20140128683 | Sternal Retractor - Devices and methods for sternal retraction that reduces bleeding from the cut edges of a sternum and reduces fracturing of the sternum during retraction. The devices and methods involve the use of sternal retractor blades having a certain geometry and inserts placed inside the sternal retractor blades during retraction of the sternotomy incision. The blades and inserts act to tamponade the blood flow from the cut sternal edge and reduce fracturing of the sternum during retraction. | 05-08-2014 |
20140127314 | COMPOSITIONS, USES, AND PREPARATION OF PLATELET LYSATES - In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method. | 05-08-2014 |
20140127185 | METHODS AND COMPOSITIONS USING NEUROPROTECTIVE STEROIDS AND THROMBOLYTIC AGENTS - Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as progesterone or allopregnanolone, and a thrombolytic agent, such as tissue plasminogen activator (tPA). Also described are compositions and methods for reducing the risks of thrombolytic agent treatment using a neuroprotective steroid. | 05-08-2014 |
20140105974 | COMPOSITIONS FOR ENCAPSULATING BIOMATERIALS AND USES RELATED THERETO - This disclosure relates to compositions and methods for encapsulating biomaterials such as cells to prevent immune responses. In certain embodiments the disclosure relates to capsules comprising a cell or cells gelled in alginate coated with a layer that prevents migration of immune molecules to the cell surface and an outer capsule layer comprising non-immunogenic material optionally containing immunosuppressive agents. In certain embodiments, the cells are capable of generating insulin that emanates from the capsule. | 04-17-2014 |
20140105931 | HEPATITIS C VIRUS PARTICLES, VACCINES, COMPOSITIONS AND METHODS RELATED THERETO - This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response. | 04-17-2014 |
20140105828 | NANOPARTICLES CARING NUCLEIC ACID CASSETTES FOR EXPRESSING RNA - This disclosure relates to nanoparticles carrying nucleic acid cassettes for expressing RNA. In certain embodiments, the disclosure relates to improved methods for targeted delivery and expression of siRNAs in vivo using DNA-based siRNA-expressing nanocassettes and receptor-targeted nanoparticles. In certain embodiments, the disclosure relates to methods of targeted delivery of survivin siRNA expressing nanocassettes which enhance sensitivity of human cancer cells to anticancer agents. | 04-17-2014 |
20140105826 | REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo. | 04-17-2014 |
20140093497 | ANTI-CD40 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies. | 04-03-2014 |
20140081133 | SYSTEM AND METHODS FOR PROVIDING REAL-TIME ANATOMICAL GUIDANCE IN A DIAGNOSTIC OR THERAPEUTIC PROCEDURE - According to one aspect, a system for intraoperatively providing anatomical guidance in a diagnostic or therapeutic procedure is disclosed. In one embodiment, the system includes: a first light source configured to emit a beam of visible light; second light source configured to emit a beam of near-infrared light; a handheld probe optically coupled to the second light source; a second imaging device configured to detect visible light; a third imaging device configured to detect near-infrared light having a first predetermined wavelength; a fourth imaging device configured to detect near-infrared light having a second predetermined wavelength; a display for displaying at least one visual representation of data; and, a controller programmed to generate at least one real-time integrated visual representation of an area of interest and to display the real-time visual representation on the display for guidance during the diagnostic or therapeutic procedure. | 03-20-2014 |
20140080828 | IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO - This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising 2-((benzo[d]imidazol-2-yl)thio)-N-phenylpropanamide derivatives, N-phenyl-2-((1-phenyl-benzo[d]imidazol-2-yl)thio)propanamide derivatives, or 2-((benzo[d]imidazol-2-yl)thio)-N-(2-chloro-4-methylphenyl)propanamide derivatives. The derivatives may be substituted with one or more substituents. Typically, the pharmaceutical composition comprises a compound of Formula (I), or salt, prodrug, or ester thereof wherein X, Y, and R1 to R7 are described herein. | 03-20-2014 |
20140073833 | METHODS, SYSTEMS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR DETERMINING PATIENT SPECIFIC TREATMENT PLANNING MARGINS - Methods, systems and computer-readable storage media relate to determining individualized treatment planning margins. The methods may include processing motion data of a target obtained from at least one marker for one or more periods. Each period may include a plurality of time intervals. The processing may include processing the motion data to determine an isocenter for each time interval along at least one of the axes of motion. The axes can include the x axis, the y axis, and/or the z axis. The method may include determining motion prediction data for each of the at least one of the axes; and determining treatment planning margins for each of the at least one of the axes based on the motion prediction data. The individualized treatment margins can be smaller and more optimal because the treatment margins can incorporate patient specific patterns of motion of a target (e.g., an organ). | 03-13-2014 |
20140066395 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV. | 03-06-2014 |
20140046039 | ANTIBODIES DIRECTED AGAINST INFLUENZA - Antibodies or antibody fragments, wherein the antibody or the fragment binds HA domain of influenza virus (e.g. H1N1, H5N1, or both). Also described are cloned human antibodies that bind influenza | 02-13-2014 |
20140045936 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE - The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein. | 02-13-2014 |
20140039615 | DEVICES AND METHODS FOR SURGICAL AND PERCUTANEOUS REPAIR OF HEART VALVE LESIONS - The devices and methods relate to surgical and percutaneous repair of heart valve regions. The devices may be structured to conform to the desired shape of a specific patient. The devices may include a frame and an artificial body onto which leaflets of the valve may coapt or rest. | 02-06-2014 |
20140039375 | SYSTEMS FOR IMPLANTING AND USING A CONDUIT WITHIN A TISSUE WALL - Various embodiments of the present invention provide a conduit system including an outer lumen ( | 02-06-2014 |
20140039187 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS - The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis. | 02-06-2014 |
20140038887 | GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR, OBESITY, AND OBESITY-RELATED DISEASES AND CONDITIONS - The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof. | 02-06-2014 |
20140025163 | SYSTEMS, DEVICES AND METHODS FOR SURGICAL AND PRECUTANEOUS REPLACEMENT OF A VALVE - The systems, devices and methods relate surgical and percutaneous replacement of a valve. The devices may include a frame and artificial leaflets. The devices may include one frame or two frames. The devices may also include a stent device in which the implant valve device may be implanted. The devices may also include a valve retainer device. | 01-23-2014 |
20140024047 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF - The present disclosure provides embodiments of a new class of hydroxylated quantum dots. The quantum dots have a hydroxylated coat disposed thereon, and which serves to minimize non-specific cellular binding and to maintain the small size of quantum dot probes. Embodiments of the coated quantum dots of the disclosure are just slightly larger than the diameter of uncoated quantum dots, and are bright with high quantum yields. They are also very stable under both basic and acidic conditions. Embodiments of the hydroxylated quantum dots result in significant reductions in non-specific binding relative to that of carboxylated dots, and to protein and PEG-coated dots. Embodiments of the disclosure are advantageous in a range of biological applications where non-specific binding is a major problem, such as in multiplexed biomarker staining in cells and tissues, detection of biomarkers in body fluid samples (blood, urine, etc.), as well as live cell imaging. | 01-23-2014 |
20140023715 | POLYMER CONJUGATES TARGETING CELLS AND METHODS RELATED THERETO - This disclosure relates to polymer coated particles targeting cancer cells and methods related thereto. In certain embodiments, the disclosure relates to nanoparticles coated with amphiphilic polymers conjugated with molecules useful for targeting tumors, monitoring the location of the nanoparticles administered to a subject by MRI, and viewing the presence of the nanoparticles during optical image-guided surgery. | 01-23-2014 |
20130344165 | JAB1 INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO - This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a JAB1 blocker. | 12-26-2013 |
20130338208 | FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 12-19-2013 |
20130337471 | CELL IDENTIFICATION WITH NANOPARTICLES, COMPOSITIONS AND METHODS RELATED THERETO - The present disclosure provides a method for identifying rare or low-abundant biological entities such as Hodgkin's and Reed-Sternberg cells, circulating tumor cells in peripheral blood, circulating fetal cells, stem cells, somatic cells, HIV-infected T cells, bacteria or viruses in water, adenoviruses, enteroviruses, hepatitis A and E, dengue, Swine Flu, bovine diarrhea, and protozpa/helminthes. The method uses a suite of nanoparticle-conjugated agents to mark biological targets of interest for subsequent fluorescence imaging. In certain embodiments, the nanoparticle-conjugated agents are fluorescent semiconductor nanocrystals conjugated with antibodies with affinity for CD15, CD30, CD45, and Pax5. In certain embodiments, a method is developed to differentiate Hodgkin's and Reed-Sternberg (HRS) cells from amongst surrounding immune cells such as T and B lymphocytes with greater specificity and precision than traditional immunohistochemistry (IHC) for the diagnosis of Hodgkin's lymphoma. | 12-19-2013 |
20130337082 | NOGGIN INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO - This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a Noggin blocker. | 12-19-2013 |
20130331777 | DELIVERY DEVICES AND METHODS FOR DELIVERING THERAPEUTIC AGENTS - Devices and methods for delivering therapeutic agents use an inverted member to deliver a therapeutic agent with little or no shear stress. The inverted member may have a movable continuous surface, the movable continuous surface having a first section and a second section opposing the first section, the second section surrounding an inner cavity that is configured to hold the therapeutic agent, the inverting member being configured to deliver the therapeutic agent by inverting at least a portion of the second section. | 12-12-2013 |
20130331280 | COMPOSITIONS AND METHODS FOR FUNCTIONAL GYLCOMICS - The disclosure relates to labeling glycans and glycosphingolipids from undefined mixtures with chemical moieties that emit light when exposed to electromagnetic radiation and uses of these labeled glycans and glycosphingolipids in microarrays for research and diagnostic purposes. In certain embodiments, the disclosure relates to derivatizing glycosphingolipids with a marker. | 12-12-2013 |
20130324552 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USED RELATED THERETO - The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer. | 12-05-2013 |
20130310350 | METHOD FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCERS AND COMPOSITIONS RELATED THERETO - Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents. | 11-21-2013 |
20130308849 | SYSTEMS, METHODS AND COMPUTER READABLE STORAGE MEDIUMS STORING INSTRUCTIONS FOR 3D REGISTRATION OF MEDICAL IMAGES - Systems, methods and computer-readable storage mediums relate to processing to segment ultrasound images of an object. The processing may be based on three different planes. The processing may include applying a wavelet transform to image data in each plane to extract the texture features; and applying a trained support vector machine to classify the texture features. | 11-21-2013 |
20130302351 | ANTAGONISM OF THE VIP SIGNALING PATHWAY - The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof. | 11-14-2013 |
20130274303 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION - The present disclosure relates to methods of treating a stimulant addiction of a patient comprising administering to a patient in need a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor thereby decreasing stimulant reward, inducing aversion for the stimulant or preventing relapse in the patient. The disclosure further encompasses methods whereby a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor is determined by: characterizing the genetic profile of the patient with respect to the gene encoding dopamine beta-hydroxylase, a polymorphism therein correlating to the level of endogenous dopamine beta-hydroxylase activity in the patient before administering the therapeutic agent. | 10-17-2013 |
20130259944 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH PLATINUM PARTICLES - This disclosure relates to methods and compositions for treating cancer with platinum particles. In certain embodiments, the disclosure relates to platinum particle coated with a polysaccharide, such as a heparin or modified heparin, conjugated to a polypeptide that has affinity for a cell surface cancer marker and uses related thereto. | 10-03-2013 |
20130244964 | NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS - The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided. | 09-19-2013 |
20130240349 | EFFICIENT SYSTEM FOR PHOTOGENERATION OF REDOX MEDIATOR RADICALS AND THEIR USE FOR SOLAR-TO-FUEL CONVERSION - This disclosure relates to compositions of nanoparticles and methods of their use related thereto such as for solar-to-fuel conversion. In general, the compositions include specific nanostructures that act as photosensitizers can help provide near quantum yield for light driven redox mediator reduction and hydrogen generation. In the presence of a catalyst and redox mediator, compositions described herein can efficiently convert sunlight to hydrogen, providing a versatile approach to solar-to-fuel conversion. | 09-19-2013 |
20130225828 | IMAGING AGENTS - The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[ | 08-29-2013 |
20130225612 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO - The invention relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the invention relates to inhibitors of NADPH-oxidase. | 08-29-2013 |
20130224310 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes. | 08-29-2013 |
20130218169 | Conduit Device and System for Implanting a Conduit Device in a Tissue Wall - Various embodiments of the present invention provide a conduit device including an attaching device configured for defining a helical pathway through a tissue wall and complementary ring in cooperation for securing the device within an aperture defined in the tissue wall. Some embodiments of the present invention further provide a system for implanting a conduit device in a tissue wall. More specifically, some embodiments provide a system including a coring device for defining an aperture in a tissue by removing and retaining a tissue core and securely implanting a conduit device therein so as to provide fluid communication between a first and second surface of the tissue wall via the conduit device. | 08-22-2013 |
20130210785 | PROGESTERONE ANALOGS AND USES RELATED THERETO - This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke. | 08-15-2013 |
20130210774 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS - The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection. | 08-15-2013 |
20130190402 | Methods Of Treating Autism With mGluR5 Antagonists - mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety. | 07-25-2013 |
20130182929 | SYSTEMS, METHODS, AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR GENERATING AN IMAGE INTEGRATING FUNCTIONAL, PHYSIOLOGICAL AND ANATOMICAL IMAGES - Systems, methods and computer-readable storage mediums relate to generating an image that includes functional, anatomical, and physiological images. The generated image may be an integrated image based on the functional image on which the anatomical and physiological images are mapped. The generated image may indicate more than one location of optimal lead placement. The generated image may be useful in pre-planning cardiac intervention procedures. | 07-18-2013 |
20130177222 | SYSTEMS, METHODS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR GENERATING AN IMAGE SERIES - Systems, methods, and computer-readable storage media relate to generate an image series that includes a patient image and a medical image. The patient image and the medical image may be associated based on identification information. | 07-11-2013 |
20130164218 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES ASANTICANCER AND IMAGING AGENTS - This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein. | 06-27-2013 |
20130158082 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO - The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I. | 06-20-2013 |
20130157988 | SUBSTITUTED ANDROST-4-ENE DIONES - The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders. | 06-20-2013 |
20130150332 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 06-13-2013 |
20130149214 | MICROVASCULAR FLUIDIC DEVICES, SYSTEMS AND METHODS RELATED THERETO - Microfluidic devices and processes are provided that relate to microvascular-sized systems configured to identify specific pathophysiological characteristics related to the interactions between, for example, blood cells and endothelial cells combined with geometric and flow constraints of microvasculature. The device may include at least one layer, the layer including a plurality of microvascularized-sized fluidic channels, the plurality of microfluidic channels being disposed in a geometric pattern. The layer may be composed of a hydrogel and/or a silicon elastomer. The channels may include subchannels of different lengths. | 06-13-2013 |
20130137760 | GAMBOGIC AMINE, A SELECTIVE TRKA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 05-30-2013 |
20130137634 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO - The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. | 05-30-2013 |
20130131157 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 05-23-2013 |
20130123618 | Imaging Agents - This invention provides amino acid derivatives useful in detecting and evaluating brain and body tumors, including (1S,2S) anti-2-[ | 05-16-2013 |
20130123185 | METHODS OF TREATING AND DIAGNOSING ACUTE CHEST SYNDROME - In certain embodiments, the disclosure relates to methods of treating or preventing organ inflammation or failure such as pulmonary inflammation comprising administering a heme scavenger such as hemopexin to a subject in need thereof. The subject may be diagnosed with higher than normal levels of protein-free plasma heme or a hemolytic disorder such as sickle cell disease, autoimmune hemolytic anemia, or paroxysmal nocturnal hemoglobinuria or acute lung injury or acute chest syndrome. Typically, the hemopexin is recombinant human hemopexin. | 05-16-2013 |
20130122514 | METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO | 05-16-2013 |
20130116275 | INHIBITORS OF HIF AND ANGIOGENESIS - Inhibitors of the Hypoxia Inducible Factor (HIF) and angiogenesis and their methods of use including the treatment of cancer, hypoxia related pathologies, disorders leading to ischemia, for example stroke and ischemic heart disease, and non-cancerous angiogenic diseases are provided. | 05-09-2013 |
20130109628 | MICRORNA COMPOSITIONS AND METHODS RELATED THERETO | 05-02-2013 |
20130095042 | SILICA-BASED NANOPARTICLES AND METHODS OF STIMULATING BONE FORMATION AND SUPPRESSING BONE RESORPTION THROUGH MODULATION OF NF-KB - Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed with natural bone targeting capabilities and expressing potent pro-osteoblastogenic and concomitant anti-osteoclastogenic activities in vitro and the capacity to increase bone mineral density in vivo. Embodiments of the disclosure can achieve their stimulatory effects on osteoblasts, and inhibitory effects on osteoclasts, in part by suppressing NF-KB signal transduction. Embodiments of the present disclosure provide for derivatives of silica-based nanoparticles that represent a novel class of dual anti-catabolic and pro-anabolic agents that may be applicable to the amelioration of numerous osteoporotic conditions. | 04-18-2013 |
20130085383 | SYSTEMS, METHODS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR IMAGE-GUIDED THERAPIES - Systems, methods, and computer-readable storage media relate to providing image guidance that can improve the accuracy of interventional procedures, such biopsy sampling, for example, by accurately providing location information to guide the biopsy needle image. The systems, methods, and computer-readable storage media include generating a 3D multi-modality image that includes a pre-procedure reference image and an ultrasound image; and displaying at least one view, one of the views including a display in-real-time of a position of the interventional device on the multi-modality image with respect to the target site during the procedure. | 04-04-2013 |
20130073054 | TISSUE SUPPORT STRUCTURE - An apparatus includes a component having a shape memory material. The shape memory material has a first shape including a substantially elongate segment. The shape memory material has a second shape including a helix having a first ring and a second ring configured to exert a compressive force on a membrane interleaved between the first ring and the second ring and lying in a plane substantially perpendicular to an axis of the helix, the shape selectable based on an external stimulus. | 03-21-2013 |
20130065267 | CONJUGATES AND METHODS FOR MEASURING CHAPERONE-MEDIATED AUTOPHAGY - This disclosure relates to methods of detecting chaperone-mediated autophagy. In some embodiments, the disclosure relates to methods of measuring chaperone-mediated autophagy in living cells and in purified lysosomes. In some embodiments, the disclosure relates to methods of detecting, diagnosing, monitoring, and/or treating lysosomal diseases in a subject. | 03-14-2013 |
20130064807 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present disclosure include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent. In one embodiment, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered. The present disclosure further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 03-14-2013 |
20130059314 | FRET-BASED METHOD FOR THE DETERMINATION OF PROTEIN PHOSPHATASE AND KINASE ACTIVITY - This disclosure relates to methods of determining activities of protein phosphatases and kinases. The disclosure further relates to methods of clinical monitoring of calcineurin activity and immunosuppression in patients and which may be used to predict transplant acceptance in patients. | 03-07-2013 |
20130045203 | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP - This disclosure relates to methods of treating or preventing cancer comprising administering a pharmaceutical composition comprising noscapine or noscapine derivatives to a subject diagnosed with a mutated adenomatous polyposis coli (APC) gene. | 02-21-2013 |
20130040947 | TRKB AGONISTS AND METHODS OF USE - Compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering a 7,8-di-hydroxyflavone derivative with modified flavone or heterocyclic ring to a subject in need thereof. Methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. | 02-14-2013 |
20130034552 | TEMPERATURE SENSITIVE CONJUGATE COMPOSITIONS, AND USES RELATED THERETO - This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody. | 02-07-2013 |
20130030523 | ANNULOPLASTY RINGS AND METHODS FOR HEART VALVE REPAIR - An annuloplasty ring, configured for implantation in the annulus of a heart valve, comprising multiple segments each of which are geometrically shaped from a three dimensional perspective to conform to the anatomic shape of the valve annulus. In one embodiment, the annuloplasty ring is configured to facilitate a reduction of tension on heart valve tissue and eliminate a substantial portion of potential pressure or force that may be applied to the atrioventricular node by the annuloplasty ring when implanted. In another embodiment, at the annuloplasty ring is configured to include an assembly that facilitates selective adjustment of a segment's respective length and/or shape. The adjustment of the length of one of the ring segment's results in an adjustment of at least one angle between at least one set of other ring segments, thereby causing an adjustment to the geometric characteristics of the ring. | 01-31-2013 |
20130005837 | CANCER BIOMARKERS TO PREDICT RECURRENCE AND METASTATIC POTENTIAL - Described herein are methods for predicting recurrence, progression, and metastatic potential of a prostate cancer in a subject. In certain embodiments, the methods comprise analyzing a sample from a subject for aberrant expression patters of one or more biomarkers disclosed herein. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer. | 01-03-2013 |
20130005656 | Modified Factor VIII - Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes. | 01-03-2013 |
20120328568 | COMPOSITIONS AND USES OF LECTINS - The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection. | 12-27-2012 |
20120322895 | BIODEGRADABLE POLYMERIC NETWORKS AND METHODS FOR MANUFACTURING THE SAME - Methods of manufacturing a three-dimensional, biodegradable, thermoset polymeric network composition having desirable degradation and mechanical properties, comprising a macromer component cross-linked with a monofunctional acrylate-containing component. The macromer component can comprise a diacrylate-containing component polymerized with an amine-containing component, wherein the molar ratio of the diacrylate-containing component to the amine-containing component is greater than or equal to 1. | 12-20-2012 |
20120322144 | MICROFLUIDIC DEVICES AND SYSTEMS - A device may be configured to allow manipulation of the cell(s), such as test or drug applications, independent of the operation and/or structure of the device. The device may be configured to separate, hold and release at least one cell suspended in a fluid. The device may include a region configured to receive the fluid including at least one cell; a cell holding device that is in open communication with the region and includes at least one cell isolation region configured to releasably separate and hold each cell; and a passage that is configured to receive and supply pressure to the cell holding device. The device may further include a second region that includes the cell holding device and is in fluid communication with the region. | 12-20-2012 |
20120302575 | Methods for Preventing Oxidative Stress Injury of a Tissue by a Folate-Tempol Conjugate. - The present disclosure is generally related to methods of preventing oxidative stress injury induced by renal is-chemia-reperfusion by a Folate-TEMPOL conjugate. | 11-29-2012 |
20120302565 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF - The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors. | 11-29-2012 |
20120294803 | CXCR4 ANTAGONISTS FOR IMAGING OF CANCER AND INFLAMMATORY DISORDERS - The invention provides radiolabeled CXCR4 antagonists, compositions and methods of use for imaging of chemokine CXCR4 receptors and biological conditions associated with the expression of CXCR4 receptors, including cancer, metastasis, and inflammatory disorders. | 11-22-2012 |
20120294503 | SYSTEMS, METHODS AND COMPUTER READABLE STORAGE MEDIUMS STORING INSTRUCTIONS FOR APPLYING MULTISCALE BILATERAL FILTERING TO MAGNETIC RESONANCE (RI) IMAGES - Systems, methods and computer-readable storage mediums relate to segmenting MR images using multiscale bilateral filtering. Before the multiscale bilateral filtering, the MR images are transformed from the Image Domain to the Radon Domain. | 11-22-2012 |
20120277222 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 11-01-2012 |
20120277178 | COMPOSITIONS AND METHODS FOR TREATING FRAGILE X PREMUTATION RVGG REPEATS-MEDIATED TOXICITY - Compositions and methods of treatment or prophylaxis of fragile-X associated disorders are provided, as well as methods of screening compounds and kits to screen a library of compounds. | 11-01-2012 |
20120270788 | Method of Administering Porcine B-Domainless fVIII - The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively. | 10-25-2012 |
20120264592 | COMPOSITIONS, MATERIALS INCORPORATING THE COMPOSITIONS, AND METHODS OF USING THE COMPOSITIONS AND MATERIALS - The invention relates to composition and methods of using described compositions as oxidative catalysis. In certain embodiments, the invention relates to a composition having a nitrogen oxide species, bromide ion, a metal, and oxygen. In certain embodiments, the composition catalyzes sulfides. | 10-18-2012 |
20120264217 | RESPIRATORY SYNCYTIAL VIRUS EXPRESSION VECTORS - In certain embodiments, the disclosure relates to vectors containing bacterial nucleic acid sequences and a paramyxovirus gene. Typically, the expression vector comprises a bacterial artificial chromosome (BAC), and a nucleic acid sequence comprising a respiratory syncytial virus (RSV) gene in operable combination with a regulatory element and optionally a reporter gene. | 10-18-2012 |
20120251537 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS - PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. | 10-04-2012 |
20120231015 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO - The invention relates to fragile X mental retardation protein (FMKP), compositions, and methods related thereto. In certain embodiments, the invention relates to treating a neurological disorder by administering a P | 09-13-2012 |
20120226260 | METHODS AND DEVICES FOR DRUG DELIVERY TO OCULAR TISSUE USING MICRONEEDLE - Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye. | 09-06-2012 |
20120196870 | COMBINATION THERAPY AND CANCER - The disclosure relates to methods of treating tuberous sclerosis in a subject, comprising administering a composition comprising an mTOR inhibitor and a tyrosine kinase inhibitor to a subject that is diagnosed with, suspected of, or exhibiting symptoms of cancer. In some embodiments, the cancer is tuberous sclerosis. In some embodiments, the mTOR inhibitor is sirolimus and the tyrosine kinase inhibitor is imatinib. In some embodiments, the disclosure relates to a composition comprising an mTOR inhibitor and a tyrosine kinase inhibitor. In some embodiments, the disclosure relates to a composition comprising sirolimus and imatinib. | 08-02-2012 |
20120190847 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 07-26-2012 |
20120189620 | METHODS FOR TREATING NON-FUNCTIONING PITUITARY ADENOMA - The disclosure is directed to methods for treating non-functioning pituitary adenomas with alpha-folate receptor (“FR-α”) and compositions. In some embodiments, the disclosure is directed to a method for treating a pituitary adenoma that includes administering farletuzumab to a subject diagnosed with a non-functioning pituitary adenoma. | 07-26-2012 |
20120149645 | COMPOSITIONS AND MODULATION OF MYOCYTE ENHANCER FACTOR 2 (MEF2) - The disclosure relates to mitochondrial myocyte enhancer factor 2 (MEF2), Parkinson's disease, and other related diseases. In certain embodiments, the disclosure relates to analyzing the levels of mitochondrial MEF2 isoforms and/or its mitochondrial target gene ND6 in peripheral blood cells such as white blood cells as an indicator for neuronal mitochondrial MEF2 or ND6 and correlated the level to disease diagnosis, treatment, and prognosis. | 06-14-2012 |
20120142627 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV and HBV, in human patients or other animal hosts. The compounds are certain 6-substituted-2-amino-purine dioxolane monophosphates or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. | 06-07-2012 |
20120130282 | TARGETING THERAPEUTIC AGENTS - Provided are devices, systems, and methods for targeted administration of therapeutic agents to a subject. For example, provided are devices, systems, and methods for targeting the administration of peri-urethral bulking agents. | 05-24-2012 |
20120123205 | ADDITIONAL SYSTEMS AND METHODS FOR PROVIDING REAL-TIME ANATOMICAL GUIDANCE IN A DISGNOSTIC OR THERAPEUTIC PROCEDURE - A system and method for intra-operatively providing anatomical guidance in a diagnostic or therapeutic procedure is disclosed. In embodiments, the system includes multiple light sources configured to emit different frequencies, multiple electronic imaging devices to detect various frequencies of reflected, emitted, or scattered light. The system and method incorporate an optical probe is integral to an endoscopic device or a therapeutic laser system, optically coupled to a light source; a display for displaying at least one visual representation of data; and a controller programmed to generate at least one real-time integrated visual representation of an area of interest and to display the real-time visual representation on the display for guidance during the diagnostic or therapeutic procedure. | 05-17-2012 |
20120108650 | MICRO RNA MARKERS AND METHODS RELATED THERETO - The present invention provides methods of diagnosis of Alzheimer's disease including assessing the levels of certain microRNAs in a subject and comparing these to levels in subjects not exhibiting the disease. The identified measurements provide input for improved diagnoses of Alzheimer's disease as compared to certain other forms of dementias, which allows more effective treatment regimens. | 05-03-2012 |
20120108510 | METHODS OF IMPROVING BEHAVIORAL THERAPIES - This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy. | 05-03-2012 |
20120107902 | Processes For Forming Amide Bonds And Compositions Related Thereto - The disclosure relates to methods for producing amide bonds and reagents related thereto. In some embodiments, the disclosure relates to methods of producing an amide comprising mixing an O-silylated thionoester and an amine under conditions such that an amide is formed. In another embodiment, the disclosure relates to mixing a thiolacid, a silylating agent, and an amine under conditions such that an amide is formed. | 05-03-2012 |
20120083713 | DEVICE FOR GAUGING A FORCE THRESHOLD AND ENGAGING A TARGET OF INTEREST - The disclosure generally relates to devices and instruments for engaging a target of interest, having a resilient member for gauging a force threshold. The device or instrument may include a tip portion, wherein the tip portion includes a first end portion a having an engaging member configured to engage a target of interest, an opposite, second end portion, and a body portion defined therebetween, the body portion including a resilient member configured to be elastically compressible up to a predetermined maximum compression level. | 04-05-2012 |
20120076820 | CD40L VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO - The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed on viral like particle as an adjuvant, in combination with a viral antigen, to vaccinate a subject. | 03-29-2012 |
20120071539 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST - Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic compositions comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided. | 03-22-2012 |
20120059282 | INTERNET-BASED COGNITIVE DIAGNOSTICS USING VISUAL PAIRED COMPARISON TASK - Disclosed are methods for diagnosing declarative memory loss using mouse tracking to follow the visual gaze of a subject taking a visual paired comparison test. Also disclosed are methods for diagnosing dementia such as mild cognitive impairment and Alzheimer's disease. | 03-08-2012 |
20120058978 | METHOD FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCERS AND COMPOSITIONS RELATED THERETO - Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents. | 03-08-2012 |
20120040924 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV. | 02-16-2012 |
20120029932 | DISPLAY OF PATIENT-SPECIFIC DATA - Systems, methods, and computer-program products identify clinical data corresponding to a plurality of patients located within a common health care delivery unit, and apply one or more rules to at least some of the clinical data using at least one quality and/or safety measure-specific specification. Based on the application of the rules, one or more care indicators corresponding to the plurality of patients are displayed in a single interface, the one or more care indicators indicating whether one or more of the patients is receiving appropriate care. | 02-02-2012 |
20120028977 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions - Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed. | 02-02-2012 |
20120027666 | POLYOXOMETALATE WATER OXIDATION CATALYSTS AND METHODS OF USE THEREOF - Homogeneous water oxidation catalysts (WOCs) for the oxidation of water to produce hydrogen ions and oxygen, and methods of making and using thereof are described herein. In a preferred embodiment, the WOC is a polyoxometalate WOC which is hydrolytically stable, oxidatively stable, and thermally stable. The WOC oxidized waters in the presence of an oxidant. The oxidant can be generated photochemically, using light, such as sunlight, or electrochemically using a positively biased electrode. The hydrogen ions are subsequently reduced to form hydrogen gas, for example, using a hydrogen evolution catalyst (HEC). The hydrogen gas can be used as a fuel in combustion reactions and/or in hydrogen fuel cells. The catalysts described herein exhibit higher turn over numbers, faster turn over frequencies, and/or higher oxygen yields than prior art catalysts. | 02-02-2012 |
20120022086 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS - Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the treatment of disorders including neurological disorders, neuropsychiatric disorders, and metabolic disorders are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes administering to the subject a therapeutically effective amount of the described compounds. A further method of promoting neuroprotection in a subject also is provided, which includes administering to the subject a therapeutically effective amount of the described compounds. | 01-26-2012 |
20120022070 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use - Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors are disclosed. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases and conditions, such as inflammation and neurodegenerative disorders. Methods of treating and preventing cancer and other Hsp90 related diseases and conditions are disclosed that include administering to the subject a therapeutically effective amount of an Hsp90 inhibitor. Methods of preparing the novel Hsp90 inhibitors are also provided. | 01-26-2012 |
20110319416 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions - Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-E, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed. | 12-29-2011 |
20110306579 | METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D - Described herein are compositions and methods for treating or preventing nervous system injury. In particular, the methods and compositions relate to the use of at least one neuroprotective steroid, such as progesterone, and vitamin D. | 12-15-2011 |
20110305636 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT - Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled triamino-pyridine derivatives, methods of synthesizing these compounds, intermediate compounds, methods of treatment using these compounds, methods of imaging, diagnosing, localizing, monitoring, and/or assessing a condition (e.g., corticotropin releasing factor type-1 (CRF1)) and/or related biological events, using triamino-pyridine derivatives, and the like. In addition, the present disclosure includes compositions (e.g., labeled triamino-pyridine derivatives that are ligands for the CRF1 receptor) used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging or SPECT imaging). | 12-15-2011 |
20110294844 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 12-01-2011 |
20110288044 | Modulation of sodium channels by nicotinamide adenine dinucleotide - The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD | 11-24-2011 |
20110286919 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER - The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor α (FRa) receptor. | 11-24-2011 |
20110282587 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY - Described herein are computer-readable storage mediums, methods and systems useful for analyzing samples via mass spectrometry. Aspects described herein include methods for normalizing mass spectrometry data that include providing a reference set of mass spectrometry data obtained from a first external standard sample having one or more isotopic standards, wherein the reference set of mass spectrometry data comprises one or more m/z intensity ratios. Methods described herein are useful for reducing errors based on instrument response and ionization efficiencies and improve reproducibility of data from instrument to instrument and from day to day. | 11-17-2011 |
20110282081 | Methods of Preparing 1-Deoxy-Sphingoid Bases and Derivatives Thereof - Novel methods of synthesizing 1-deoxy-sphingoid bases and derivatives are disclosed. The synthesis is achieved from commercially available and inexpensive starting materials. The process includes thioesterification, cross-coupling, and reduction. The process may also include directed epoxidation, regioselective epoxide-opening, hydrogenation, and dihydroxylation. The methods described herein provide 1-deoxy-sphingoid bases and derivatives in high overall yield and high enantiomeric purity. | 11-17-2011 |
20110281908 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use - Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors and methods for making these classes are provided herein. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases, such as inflammation and neurodegenerative disorders. Also provided herein are methods of treating and preventing cancer and other Hsp90 related disease. The methods include administering to a subject a therapeutically effective amount of an Hsp90 inhibitor. | 11-17-2011 |
20110275839 | COMPOUNDS, INTERMEDIATES, AND METHODS OF PREPARING THE SAME - The present disclosure provides optionally substituted seven-membered ring isomers of naturally occurring carbohydrate compounds, methods of synthesizing these compounds, intermediate compounds, methods of synthesizing the intermediate compounds, and the like. | 11-10-2011 |
20110274651 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition - Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by inhibiting the cytoplasmic transport mechanisms within the cells. The compositions described herein include an effective amount of the noscapine analogues described herein, along with a pharmaceutically acceptable carrier or excipient. The compositions can also include one or more additional antimicrobial compounds. | 11-10-2011 |
20110235884 | Atlas-Assisted Synthetic Computed Tomography Using Deformable Image Registration - Disclosed are systems for and methods of creating a synthetic image by registering a reference or atlas image to a clinical image using both rigid and deformable image registration algorithms. In some embodiments, a synthetic computed tomography (CT) image may be created by registering an atlas CT image to a clinical image such as an MR scan. Rigid registration in some embodiments may be followed by a smoothing B-spline transform algorithm with a mutual information similarity metric and an optimizer; followed then by an image signal intensity algorithm with displacement vectors at each voxel and diffeomorphic transformations. | 09-29-2011 |
20110230361 | PROSTATE CANCER BIOMARKERS TO PREDICT RECURRENCE AND METASTATIC POTENTIAL - Described herein are methods for predicting the recurrence, progression, and metastatic potential of a prostate cancer in a subject. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of FOXO1A, SOX9, CLNS1A, PTGDS, XPO1, LETMD1, RAD23B, ABCC3, APC, CHES1, EDNRA, FRZB, HSPG2, and TMPRSS2_ETV1 FUSION. The method can further comprise detecting in a sample from a subject one or more biomarkers selected from the group consisting of miR-103, miR-339, miR-183, miR-182, miR-136, and miR-221. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer. | 09-22-2011 |
20110224752 | MICROELECTRODE STIMULATION FOR TREATMENT OF EPILEPSY OR OTHER NEUROLOGIC DISORDER - Methods for treating a neurologic disorder by neurostimulation. The stimulation may be applied using electromagnetic energy. In certain embodiments, distributed electrical stimulation is applied to a target site of the brain in an ongoing fashion. A microelectrode array may be used to provide the distributed electrical stimulation. The method may also comprise the detection of electrophysiologic signals from the brain. These detected signals may be analyzed and used for closed-loop feedback of the neurostimulation. Also provided are systems for neurostimulation and software for operating such systems. | 09-15-2011 |
20110206699 | Methods for the Treatment of Graft-Versus-Host Disease - Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject. | 08-25-2011 |
20110189236 | Methods and Compositions for the Display of Polypeptides on the Pili of Gram-Positive Bacteria - Provided herein are methods and compositions for the display of polypeptides of interest on the tip of pili of Gram-positive bacteria. According to the present invention, the polypeptide of interest is amino terminal to a Gram-positive bacterial pilus tip protein or an active variant or fragment thereof, wherein the active variant or fragment comprises a cleaved cell wall sorting signal (CWSS) motif. The Gram-positive bacterium displaying a polypeptide of interest on the tip of pili that are disclosed herein are useful, for example, in methods for immunizing a subject with an antigen and methods for removing contaminants from a composition. | 08-04-2011 |
20110144196 | TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF - Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. | 06-16-2011 |
20110144096 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 06-16-2011 |
20110129496 | Use of mTOR Inhibitors to Enhance T Cell Immune Responses - It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog. | 06-02-2011 |
20110105343 | Systems Biology Approach Predicts Immunogenicity of Vaccines - A major challenge in vaccinology is to prospectively determine vaccine efficacy. Disclosed herein are methods and compositions for identifying early expression “signatures” that predicted immune responses in humans vaccinated with a vaccine. | 05-05-2011 |
20110085974 | SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY - The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue. | 04-14-2011 |
20110077293 | GAMBOGIC AMINE, A SELECTIVE TrkA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 03-31-2011 |
20110070166 | REDUCED DYE PROBES FOR THE DETECTION OF RADICAL OXYGEN SPECIES - Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo. | 03-24-2011 |
20110064675 | ELEMENTAL IRON NANOPARTICLES - Synthesis of iron nanoparticles with a substantially unoxidized iron core and a biocompatible coating is described. The nanoparticles are formed by reacting an iron salt solution with a reducing agent in a substantially oxygen-free environment and exposing the formed iron particles to a biocompatible coating agent in a substantially oxygen-free environment to form coated iron particles. An average diameter of the coated iron particles is between 5 nm and 25 nm. The biocompatible coating can functionalized with cell-specific agents for use as diagnostic and therapeutic agents. | 03-17-2011 |
20110064656 | Methods of Determining Renal Function using Technetium-99m Tricarbonyl-nitrilotriacetic acid - This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer | 03-17-2011 |
20110060036 | Branched Multifunctional Nanoparticle Conjugates And Their Use - Disclosed herein are compounds and compositions including a polyglycerol nanocarrier, a therapeutic agent or imaging agent, and optionally a targeting agent. In certain aspects the disclosed compounds include biocompatible hyperbranched polymer nanocarriers. Such compounds and compositions are useful for the targeted delivery of antitumor agents and imaging agents to tumors in vivo. Methods are also disclosed for detecting and treating such tumors. | 03-10-2011 |
20110033382 | Imaging Agents - This invention provides amino acid derivatives useful in detecting and evaluating brain and body tumors, including (1S,2S) anti-2-[18F]FACPC and (1R,2R) anti-2-[18F]FACPC. | 02-10-2011 |
20110028985 | CONDUIT DEVICE AND SYSTEM FOR IMPLANTING A CONDUIT DEVICE IN A TISSUE WALL - Various embodiments of the present invention provide a conduit device including an attaching device configured for defining a helical pathway through a tissue wall and complementary ring in cooperation for securing the device within an aperture defined in the tissue wall. Some embodiments of the present invention further provide a system for implanting a conduit device in a tissue wall. More specifically, some embodiments provide a system including a coring device for defining an aperture in a tissue by removing and retaining a tissue core and securely implanting a conduit device therein so as to provide fluid communication between a first and second surface of the tissue wall via the conduit device. | 02-03-2011 |
20110028418 | USE OF GABBA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS | 02-03-2011 |